AI Article Synopsis
- Lymphocytic gastritis (LyG) is a histopathological finding that lacks clear clinical significance but has a prevalence of 0.21% among a study of 1.5 million patients, with a higher occurrence in males and those aged 50-70.
- LyG shows associations with conditions like Helicobacter pylori infection, coeliac disease, and microscopic colitis, with gastrointestinal symptoms like anemia, diarrhea, and weight loss more common in affected individuals.
- The majority of LyG cases are believed to be self-limiting, often resolving within a year, regardless of the presence of H. pylori infection.
Article Abstract
Background: Lymphocytic gastritis (LyG) is a histopathologic finding of unknown clinical relevance.
Aims: To explore the clinical epidemiology of LyG and its associations with Helicobacter pylori (Hp) infection, coeliac disease (CD) and microscopic colitis (MC) METHODS: In a cross-sectional study, the demographic, clinical, and histopathologic data of patients with and without LyG were compared. Between 2008 and 2020, 1.5 million patients with endoscopic biopsies of the gastroduodenal mucosa were extracted from a database. LyG diagnoses were reviewed to collect detailed information regarding its topographic distribution within the stomach. In a large subgroup of 400 000 patients, tissue samples from the colon were also available.
Results: Of 1 481 336 patients, 341 had LyG with Hp and 2697 had Hp-negative LyG (with an overall prevalence of 0.21%). In patients with Hp-negative LyG, 450 (17%) had corpus-predominant LyG, 1068 antrum-predominant LyG (40%), and 1179 pangastric LyG (44%). LyG was more common in males and in subjects aged 50-70 years. There was no significant ethnic variation. Anaemia, diarrhoea, and weight loss were more common in patients with than without LyG. In 35% and 19% of patients, LyG was associated with CD and MC, respectively. All 72 patients with Hp-positive LyG and 280 of 310 patients with Hp-negative LyG with follow-up biopsies became free of LyG within a year.
Conclusions: Most cases of LyG may represent a self-limited expression, frequently associated with other GI conditions, such as Hp infection, CD, and MC. In most patients, LyG is likely to resolve within a year after its initial diagnosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/apt.16621 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-world cost-effectiveness of multi-gene panel sequencing to inform therapeutic decisions for advanced non-small cell lung cancer: a population-based study.
Lancet Reg Health Am
December 2024
Cancer Control Research, BC Cancer Research Institute, Vancouver, BC, Canada.
Article Synopsis
- * They used a retrospective design to match patients receiving the multi-gene test to those undergoing single-gene testing, focusing on survival outcomes and costs from a healthcare payer's perspective.
- * Results showed that multi-gene panel testing had longer turnaround times and slightly increased costs, but it also resulted in marginally better survival rates; however, the overall net monetary benefit was inconclusive, with varying cost-effectiveness results across multiple scenarios.
Integrating network pharmacology and multi-omics to explore the mechanism of Callicarpa kwangtungensis Chun in ameliorating Alzheimer's disease pathology in APP/PS1 mice.
J Ethnopharmacol
January 2025
National Key Laboratory for the Modernization of Classical and Famous Prescriptions of Chinese Medicine, Nanchang, Jiangxi, 330096, PR China; Research and Development Department, Jiangzhong Pharmaceutical Co., Ltd., Nanchang, Jiangxi, 330103, PR China; School of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, 330004, PR China. Electronic address:
Ethnopharmacological Relevance: Callicarpa kwangtungensis Chun (CK) is a traditional herb for the treatment of blood stasis, hemostasis, anti-inflammation, and antidepressant. Previous studies have showen that CK extract has significant anti-neuroinflammatory activity. However, the mechanism by which it treats AD is still unclear.
View Article and Find Full Text PDFUsing Genomic Heterogeneity to Inform Therapeutic Decisions for Metastatic Colorectal Cancer: An Application of the Value of Heterogeneity Framework.
Appl Health Econ Health Policy
November 2024
Canadian Centre for Applied Research in Cancer Control, BC Cancer, Vancouver, BC, Canada.
Background And Objective: Mutations in KRAS and NRAS are predictive of poor response to cetuximab and panitumumab, two anti-epidermal growth factor receptor (EGFR) monoclonal antibodies used in metastatic colorectal cancer (mCRC). Our objective was to explore the value of using KRAS and NRAS mutation status to inform third-line anti-EGFR therapy for mCRC using the value of heterogeneity (VOH) framework.
Methods: We used administrative data to identify mCRC patients who were potentially eligible for third-line therapy in 2006-2019 in British Columbia (BC), Canada.
What COVID-19 Vaccination Strategy Should Be Implemented and Which Vaccines Should Be Used in the Post-Pandemic Era?
Vaccines (Basel)
October 2024
College of Physicians of Barcelona, 08017 Barcelona, Spain.
COVID-19 vaccines have reduced the negative health and economic impact of the COVID-19 pandemic by preventing severe disease, hospitalizations and deaths. In the new socio-economic normality, the COVID-19 vaccination strategy can be universal or high-risk and seasonal or not seasonal, and different vaccines can be used. The universal vaccination strategy can achieve greater health and herd immunity effects and is associated with greater costs than the high-risk vaccination strategy.
View Article and Find Full Text PDFAssessment of NSCLC disease burden: A survival model-based meta-analysis study.
Comput Struct Biotechnol J
December 2024
I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
We present a meta-analytics approach to quantify NSCLC disease burden by integrative survival models. Aggregated survival data from public sources were used to parameterize the models for early as well as advanced NSCLC stages incorporating chemotherapies, targeted therapies, and immunotherapies. Overall survival (OS) was predicted in a heterogeneous patient cohort based on various stratifications and initial conditions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!